Paul Tudor Jones Prothena Corp Public LTD CO Transaction History

Tudor Investment Corp Et Al

$25.1 Billion
Q4 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 27,398 shares of PRTA stock, worth $409,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,398

Previous 27,531 0.48%

Holding current value

$409,600

Previous $460,000 17.61%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$11.95 - $18.35 $1,589 - $2,440	-133 Reduced 0.48%	27,398 $379,000
Q3 2024 Nov 14, 2024	BUY	$16.73 - $24.79 $12,313 - $18,245	736 Added 2.75%	27,531 $460,000
Q2 2024 Aug 14, 2024	BUY	$19.54 - $26.15 $523,574 - $700,689	26,795 New	26,795 $553,000
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $922,805 - $1.49 Million	28,561 New	28,561 $1.04 Million
Q1 2023 May 15, 2023	BUY	$46.97 - $58.27 $1.36 Million - $1.69 Million	29,008 New	29,008 $1.41 Million
Q2 2022 Aug 15, 2022	BUY	$22.73 - $39.98 $533,223 - $937,890	23,459 New	23,459 $637,000
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $1.15 Million - $2 Million	-27,280 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$48.2 - $78.89 $615,947 - $1.01 Million	-12,779 Reduced 31.9%	27,280 $1.94 Million
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $866,476 - $2.31 Million	40,059 New	40,059 $2.06 Million
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $148,288 - $204,262	-14,653 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$9.93 - $13.47 $145,504 - $197,375	14,653 New	14,653 $146,000
Q2 2020 Aug 14, 2020	SELL	$9.56 - $12.51 $207,671 - $271,754	-21,723 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$7.54 - $15.77 $74,427 - $155,665	9,871 Added 83.29%	21,723 $232,000
Q4 2019 Feb 14, 2020	SELL	$7.48 - $17.01 $263,243 - $598,632	-35,193 Reduced 74.81%	11,852 $188,000
Q3 2019 Nov 14, 2019	SELL	$6.89 - $10.45 $1,708 - $2,591	-248 Reduced 0.52%	47,045 $369,000
Q2 2019 Aug 14, 2019	BUY	$8.85 - $12.49 $148,857 - $210,081	16,820 Added 55.2%	47,293 $500,000
Q1 2019 May 15, 2019	BUY	$10.32 - $14.49 $135,326 - $190,007	13,113 Added 75.54%	30,473 $370,000
Q4 2018 Feb 14, 2019	BUY	$8.73 - $13.74 $56,526 - $88,966	6,475 Added 59.49%	17,360 $179,000
Q3 2018 Nov 14, 2018	BUY	$12.7 - $15.79 $138,239 - $171,874	10,885 New	10,885 $142,000
Q2 2018 Aug 14, 2018	SELL	$10.99 - $44.21 $82,018 - $329,939	-7,463 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$27.95 - $45.04 $208,590 - $336,133	7,463 New	7,463 $274,000
Q4 2017 Feb 14, 2018	SELL	$35.44 - $63.76 $116,845 - $210,216	-3,297 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$53.83 - $67.75 $177,477 - $223,371	3,297	3,297 $214,000

Others Institutions Holding PRTA

# of Institutions

198

Shares Held

44.5M

Call Options Held

601K

Put Options Held

259K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $701M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account